Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) - Related Studies

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

This study is ongoing, but not recruiting participants.

Study NCT00078403. Last updated on September 25, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections
		Hepatitis C
		Liver Disease

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Hepatitis
		Infection
		Liver Diseases

3	More general conditions related to this trial
		Digestive System Diseases
		Flaviviridae Infections
		Hepatitis, Viral, Human
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Peginterferon alfa-2a
		Ribavirin

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antiviral Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)